Positive association between the plasma levels of 5-hydroxyindoleacetic acid and the severity of depression in patients with chronic obstructive pulmonary disease

BMC Psychiatry

Tomoaki Hoshino²  Naohisa Uchimura¹  Haruki Imaoka²  Nobutaka Edakuni²  Masaki Okamoto²  Kazuko Matsunaga²  Yoshihisa Shoji¹  Kosuke Ito²  Tomotaka Kawayama²  Tomomi Sekiduka-Kumano² 

[1] Department of Neuropsychiatry, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan;Division of Respirology, Neurology, and Rheumatology, Department of Medicine 1, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan

关键词: Depression;    Monoamine;    COPD;   

Others  :  1124034
DOI  :  10.1186/1471-244X-13-159

 received in 2012-10-10, accepted in 2013-05-28,  发布年份 2013

【 摘 要 】

Background

The role of plasma monoamines in patients with chronic obstructive pulmonary disease (COPD) with depression is unclear. To investigate monoamines in 20 depressed patients with COPD, the plasma concentrations of serotonin, 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid, and 3-methoxy-4-hydroxyphenylglycol (MHPG) were measured and compared with those in 50 non-depressed COPD patients, and also with 23 age- and gender-matched non-smokers and 13 smokers as non-depressed healthy controls.

Methods

Diagnosis of depression was assessed using the Centre for Epidemiologic Studies Depression Scale. Plasma concentrations of monoamines were measured by high-performance liquid chromatography.

Results

None of the depressed COPD patients had suicidal ideation. The plasma 5-HIAA level [median, (25% and 75% quartiles)] in depressed COPD patients [6.8 ng/mL, (4.9 and 13.1)] was significantly higher than in non-depressed COPD patients [5.4, (4.2 and 7.5)] (p=0.022) and non-smokers [5.1 (3.8 and 7.2)] (p=0.041), but not smokers [4.7, (4.0 and 6.7)] (p>0.05). The plasma 5-HIAA level (r=0.24, p=0.049) was significantly associated with the severity of depression in patients with COPD. The plasma MHPG level was significantly higher in depressed COPD patients (p=0.043) than in smokers, but was not higher than that in non-depressed COPD patients or non-smokers, although the level of MHPG was not associated with the severity of depression.

Conclusion

The plasma 5-HIAA level is increased in depressed COPD patients. Plasma monoamines may be a good biomarker for detection of depression in patients with COPD.

【 授权许可】

   
2013 Sekiduka-Kumano et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Mannino DM: COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002, 121(5 Suppl):121S-126S.
• [2]Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease NHLBI/WHO Workshop report. Rev. ed 2011. http://www.goldcopd.com webcite
• [3]Ito K, Kawayama T, Shoji Y, Fukushima N, Matsunaga K, Edakuni N, Uchimura N, Hoshino T: Depression, but not sleep disorder, is an independent factor affecting exacerbations and hospitalization in patients with chronic obstructive pulmonary disease. Respirology 2012, 17(6):940-949.
• [4]Schneider C, Jick SS, Bothner U, Meier CR: COPD and the risk of depression. Chest 2010, 137(2):341-347.
• [5]Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Platt RW, Wang C, Bourbeau J: Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med 2008, 178(9):913-920.
• [6]Fan VS, Ramsey SD, Giardino ND, Make BJ, Emery CF, Diaz PT, Benditt JO, Mosenifar Z, McKenna R Jr, Curtis JL: Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med 2007, 167(21):2345-2353.
• [7]Lewis KE, Annandale JA, Sykes RN, Hurlin C, Owen C, Harrison NK: Prevalence of anxiety and depression in patients with severe COPD: similar high levels with and without LTOT. COPD 2007, 4(4):305-312.
• [8]Goodwin RD: Is COPD associated with suicide behavior? J Psychiatr Res 2011, 45(9):1269-1271.
• [9]Lacasse Y, Beaudoin L, Rousseau L, Maltais F: Randomized trial of paroxetine in end-stage COPD. Monaldi Arch Chest Dis 2004, 61(3):140-147.
• [10]Hindmarch I: Expanding the horizons of depression: beyond the monoamine hypothesis. Hum Psychopharmacol 2001, 16(3):203-218.
• [11]Anderson GM: Peripheral and central neurochemical effects of the selective serotonin reuptake inhibitors (SSRIs) in humans and nonhuman primates: assessing bioeffect and mechanisms of action. Int J Dev Neurosci 2004, 22(5–6):397-404.
• [12]Lewis A, Miller JH, Lea RA: Monoamine oxidase and tobacco dependence. Neurotoxicology 2007, 28(1):182-195.
• [13]Logan J, Fowler JS: Evidence for reduced arterial plasma input, prolonged lung retention and reduced lung monoamine oxidase in smokers. Nucl Med Biol 2005, 32(5):521-529.
• [14]Mitani H, Shirayama Y, Yamada T, Kawahara R: Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(3):531-534.
• [15]Spreux-Varoquaux O, Alvarez JC, Berlin I, Batista G, Despierre PG, Gilton A, Cremniter D: Differential abnormalities in plasma 5-HIAA and platelet serotonin concentrations in violent suicide attempters: relationships with impulsivity and depression. Life Sci 2001, 69(6):647-657.
• [16]American Thoracic Society: Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995, 152(3):1107-1136.
• [17]Toda R, Hoshino T, Kawayama T, Imaoka H, Sakazaki Y, Tsuda T, Takada S, Kinoshita M, Iwanaga T, Aizawa H: Validation of “lung age” measured by spirometry and handy electronic FEV1/FEV6 meter in pulmonary diseases. Intern Med 2009, 48(7):513-521.
• [18]Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T: Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157(3 Pt 1):785-790.
• [19]Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis 1992, 145(6):1321-1327.
• [20]Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999, 54(7):581-586.
• [21]Goddard PR, Nicholson EM, Laszlo G, Watt I: Computed tomography in pulmonary emphysema. Clin Radiol 1982, 33(4):379-387.
• [22]Iwata N, Saito K, Roberts RE: Responses to a self-administered depression scale among younger adolescents in Japan. Psychiatry Res 1994, 53(3):275-287.
• [23]Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67(6):361-370.
• [24]Nebinger P, Koel M: Automatic determination of serotonin in biological fluids by liquid chromatography. J Chromatogr 1988, 427(2):326-330.
• [25]Nagaoka S, Iwamoto N, Arai H: First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment. Biol Psychiatry 1997, 41(8):857-864.
• [26]Hanai J, Kawai T, Sato Y, Takasugi N, Nishi M, Takeda T: Simple liquid-chromatographic measurement of vanillylmandelic acid and homovanillic acid in urine on filter paper for mass screening of neuroblastoma in infants. Clin Chem 1987, 33(11):2043-2046.
• [27]Heinz A, Weingartner H, George D, Hommer D, Wolkowitz OM, Linnoila M: Severity of depression in abstinent alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate concentrations. Psychiatry Res 1999, 89(2):97-106.
• [28]De Bellis MD, Geracioti TD Jr, Altemus M, Kling MA: Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biol Psychiatry 1993, 33(8–9):636-641.
• [29]Placidi GP, Oquendo MA, Malone KM, Huang YY, Ellis SP, Mann JJ: Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biol Psychiatry 2001, 50(10):783-791.
• [30]Mann JJ, Malone KM, Sweeney JA, Brown RP, Linnoila M, Stanley B, Stanley M: Attempted suicide characteristics and cerebrospinal fluid amine metabolites in depressed inpatients. Neuropsychopharmacol 1996, 15(6):576-586.
• [31]Lau WK, Chan-Yeung MM, Yip BH, Cheung AH, Ip MS, Mak JC: The role of circulating serotonin in the development of chronic obstructive pulmonary disease. PLoS One 2012, 7(2):e31617.
• [32]Engstrom G, Alling C, Blennow K, Regnell G, Traskman-Bendz L: Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls. Eur Neuropsychopharmacol 1999, 9(5):399-405.
• [33]Kapur S, Mann JJ: Role of the dopaminergic system in depression. Biol Psychiatry 1992, 32(1):1-17.
• [34]Yohannes AM, Connolly MJ: Do antidepressants work in patients with chronic obstructive pulmonary disease with comorbid depression? Expert Rev Respir Med 2011, 5(6):727-729.
• [35]Yohannes AM, Connolly MJ, Baldwin RC: A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry 2001, 16(5):451-454.